Clinical Trials Logo

Dengue Virus Infection clinical trials

View clinical trials related to Dengue Virus Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT04486638 Recruiting - Clinical trials for Dengue Virus Infection

Dengvaxia US Pregnancy Registry

DNG00044
Start date: September 7, 2022
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy

NCT ID: NCT04170140 Completed - Clinical trials for Dengue Virus Infection

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

DNG00042
Start date: January 7, 2020
Phase:
Study type: Observational

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material. The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

NCT ID: NCT04023708 Completed - Clinical trials for Dengue Virus Infection

Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

Start date: March 11, 2022
Phase:
Study type: Observational [Patient Registry]

Primary Objective: To evaluate the safety of CYD-TDV in pregnant women and their offsprings inadvertently exposed during pregnancy or up to 30 days preceding their last menstrual period (LMP) with regards to maternal, pregnancy, birth, neonatal and infant outcomes. Specifically, the frequency/rates of these outcomes will be: (i) described, and (ii) compared with population-level background incidence rates prior to the introduction of CYD-TDV immunization (i.e., external unvaccinated comparator). Secondary Objective: To describe: - the characteristics of women exposed to CYD-TDV during pregnancy or up to 30 days before the LMP - the characteristics of CYD-TDV pregnancy exposure with regards to number of doses, dose intervals, and trimester of exposure.